Showing results (191-200 of 313) with videos related to
Sort By:
Pageof 32
Blood|June 17, 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alphaHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantationYiming Chen, Jorge Cortes, Zeev Estrov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromesJorge Cortes, Stefan Faderl, Elihu Estey, et al.Blood Advances|October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapyGeoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 15, 2016
At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia CellsUri Rozovski, David M Harris, Ping Li, et al.Blood|October 24, 2002
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responsesHagop M Kantarjian, Jorge E Cortes, Susan O'Brien, et al.British Journal of Haematology|November 10, 2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)Gheath Alatrash, Maher Albitar, Susan O'Brien, et al.British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.Cancer|October 24, 2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemiaPaolo Strati, Hagop Kantarjian, Deborah Thomas, et al.Pageof 32